Quantitative tyrosine phosphoproteomics of wild type and PTPRK KO tumour xenografts
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Epithelial Cell
DISEASE(S): Colon Cancer
SUBMITTER: 
Katarzyna Wojdyla
LAB HEAD: Hayley Sharpe
PROVIDER: PXD050617 | Pride | 2024-07-03
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| HS_KW_TMTphos_230421_run1.msf | Msf | |||
| HS_KW_TMTphos_230421_run1.raw | Raw | |||
| HS_KW_pY_TMT_MS2_050521_run1.msf | Msf | |||
| HS_KW_pY_TMT_MS2_050521_run1.raw | Raw |
Items per page: 5 1 - 4 of 4 |
Similar Datasets
Project description:Pancreatic ductal adenocarcinoma is one of the most lethal cancers, with a 5 year-survival rate below 5%. Lack of curative treatment and failure of targeted therapies urge the need to identify novel efficient therapeutic strategy. Achievement of this goal will be obtained through the identification of diagnosis and prognosis biomarkers, identification of novel therapeutic targets and the knowledge of resistance mechanisms induced by these targeted therapies. PI3K/Akt/mTOR signalling, one of the most altered in cancers, is overactivated in pancreatic cancer and correlated with poor prognosis. In the Vertebrates, the family of class I phosphoinoitide-3-kinase (PI3K) includes four isoforms: p110α, p110β, p110δ and p110γ. Although they all perform the same biochemical reaction (phosphorylation of PIP2 in PIP3, a membrane lipid messenger), each isoform were demonstrated to have specific physiological roles. Global PI3K inhibitors are currently being tested in phase I/II clinical trials in advanced solid cancers, but show at maximal doses tolerated a limited therapeutic benefit. Isoform-selective PI3K inhibitors are currently the most promising agents because, at low doses, they are more efficient to inhibit one PI3K isoform, and thus, less toxic than pan-PI3K inhibitors. The objectives of this thesis are to determine isoform-specific PI3K roles and the therapeutic interest to target one or more isoforms in pancreatitis and PDAC, by the identification of isoform-specific pathways and the study of adaptive responses induced by targeting of one or all isoforms of PI3K. In a first part, my work has highlighted, validated and completed results obtained in the team, to demonstrate the significance of PI3K/Akt signalling in two physiological processes: chronic pancreatitis and initiation of pancreatic carcinogenesis. Precisely, the overactivation of PI3K/Akt pathway measured on human and murine chronic pancreatitis samples is correlated with a specific p110α activation gene expression signature. Moreover, genetic and pharmacologic inactivation of p110α during pancreatic chronic inflammation or cancerogenesis (by oncogenic Kras) prevents the formation of acino-ductal metaplasia, structures at the origin of pancreatic carcinogenesis initiation. Development of in vitro acino-ductal transdifferentiation protocol allowed me to demonstrate that only p110α is necessary at this initial step of pancreatic carcinogenesis by the regulation of Rho small GTPases, further regulating actin remodelling. In the second part, by a phosphoproteomic-based approach, I quantified PI3K downstream phosphorylation-regulated targets in a pancreatic cancer cell line treated or not by a pan- or selective PI3K inhibitor at different times. I demonstrated for the first time existence of targets, signalling pathways and adaptive responses regulated by each PI3K isoform. To conclude, all these results demonstrate the rational of combinatorial use of isoform-specific PI3K inhibitors in patients with pancreatic cancer for better clinical response
2022-02-28 | PXD008410 | Pride
Project description:The goal of this project was to build SWATH Spectral libraries to analyze phosphopeptides from colorectal cancer organoids.
2023-12-10 | PXD018862 | Pride
Project description:Despite the indisputable efficacy of kinase-inhibitors in myeloid malignancies, cure remains an exception and most patients eventually progress. Therefore, there is an unmet clinical need in developing diagnostic pipelines for the characterization of kinase-activities and signaling networks to investigate their implications in response and resistance. Here, we used the BCR-ABL1 driven K562 and hetero-/homozygote FLT3-ITD driven MOLM13/MV4-11 human myeloid cell line models exposed to the clinically established BCR-ABL1 and FLT3 kinase-inhibitors, Nilotinib and Midostaurin, respectively. Titanium dioxide enrichment with liquid chromatography tandem mass spectrometry (LC-MS) was used and the differential phosphoproteomics profiles analyzed with the Kinase-Activity Enrichment Analysis (KAEA) pipeline. This novel pipeline allows inferring kinase activities within signaling networks. We observed correct detection of expected direct (ABL, KIT, SRC) and indirect (MAPK) targets of Nilotinib as well as the indirect (PRKC, MAPK, AKT, RPS6K) targets of Midostaurin, respectively. Moreover, our pipeline was able to characterize unexplored kinase-activities within the corresponding signaling networks. With our pipeline, we provide researchers and clinicians an instrument to monitor biological behavior of kinases in response or resistance to targeted treatment. Further investigations are warranted and ongoing to determine the utility of our pipeline to characterize mechanisms of disease progression and treatment failure.
2021-09-10 | PXD024806 | Pride
Project description:We performed an unbiased investigation of changes in the proteome and the phosphoproteome of the heart induced by exercise, either in control or in PKP2-deficient hearts. Two pairs of experimental groups were studied: The first pair consisted of control animals and the second pair of animals deficient in PKP2 (PKP2cKO). For both cases, results obtained from sedentary animals were compared to those obtained from animals subjected to six weeks of a running exercise program. We therefore refer to the first pair as “control” and the second pair as “PKP2cKO” and in both cases, the variable was “exercise”. Left ventricular tissue from these animals were subjected to quantitative proteome and phosphoproteome measurements applying tandem mass tag (TMT) labeling and high-resolution mass spectrometry measurements performed on an Orbitrap QExactive mass spectrometer. For phosphoproteomic analyses, peptides were enriched by titanium dioxide chromatography and all peptide samples were pre-fractionated into 12 fractions prior to measurement.
2022-11-04 | PXD025956 | Pride
Project description:Different types of DNA damage can initiate phosphorylation-mediated signalling cascades that result in stimulus specific pro- or anti-apoptotic cellular responses. Amongst its many roles, the NF-κB transcription factor RelA is central to the DNA damage response pathway. Yet, understanding of the co-ordinated signalling mechanisms that result in these different DNA damaging agents inducing specific cellular outcomes through RelA remains unclear. Here, we examine the temporal effects of exposure of U2OS cells to either etoposide (ETO) or hydroxyurea (HU) on the phosphorylation status of RelA and its protein binding partners, using label-free quantitative phosphoproteomics. Although there were relatively few stimulus specific differences overall in the phosphorylated RelA interactome in response to either DNA damaging agent, we observed subtle, but significant changes in the phosphorylation states of the RelA bound proteins as a function of both the type of and duration of the DNA damaging agent used. The DNA double strand break (DSB) inducing ETO invoked more rapid, sustained responses than HU, with regulated targets primarily involved in transcription, cell division and (unsurprisingly) DSB repair. Kinase substrate prediction of confident, differentially regulated phosphosites suggests possible roles for CDK1 and MAPK3/ERK1 signaling, in addition to the known roles of ATM/ATR. In contrast, HU-induced replicative stress mediated more temporally dynamic regulation, with phosphoprotein components of the RelA network having known roles in rRNA/mRNA processing and translational initiation, many of which contained a 14-3-3ε binding motif. Our data thus point to differential regulation of key cellular processes and the involvement of unique signalling pathways in modulating DNA damage-specific functions of RelA.
2021-09-09 | PXD019587 | Pride
Project description:Different types of DNA damage can initiate phosphorylation-mediated signalling cascades that result in stimulus specific pro- or anti-apoptotic cellular responses. Amongst its many roles, the NF-κB transcription factor RelA is central to the DNA damage response pathway. Yet, understanding of the co-ordinated signalling mechanisms that result in these different DNA damaging agents inducing specific cellular outcomes through RelA remains unclear. Here, we examine the temporal effects of exposure of U2OS cells to either etoposide (ETO) or hydroxyurea (HU) on the phosphorylation status of RelA and its protein binding partners, using label-free quantitative phosphoproteomics. Although there were relatively few stimulus specific differences overall in the phosphorylated RelA interactome in response to either DNA damaging agent, we observed subtle, but significant changes in the phosphorylation states of the RelA bound proteins as a function of both the type of and duration of the DNA damaging agent used. The DNA double strand break (DSB) inducing ETO invoked more rapid, sustained responses than HU, with regulated targets primarily involved in transcription, cell division and (unsurprisingly) DSB repair. Kinase substrate prediction of confident, differentially regulated phosphosites suggests possible roles for CDK1 and MAPK3/ERK1 signaling, in addition to the known roles of ATM/ATR. In contrast, HU-induced replicative stress mediated more temporally dynamic regulation, with phosphoprotein components of the RelA network having known roles in rRNA/mRNA processing and translational initiation, many of which contained a 14-3-3ε binding motif. Our data thus point to differential regulation of key cellular processes and the involvement of unique signalling pathways in modulating DNA damage-specific functions of RelA.
2021-09-09 | PXD019589 | Pride
Project description:The Ptch1+/- strain constitues an established mouse model for the Shh-driven type of medulloblastoma. Combined Ptch1+/- Nos2-/- mice show a two-fold increased incidence for this tumor. Here, the impact of Nos2 inactivation on medulloblastoma development was investigated by gene expression profiling of tumor samples as well as healthy cerebellum at different ages and genotypes. Medulloblastoma samples from three Ptch1+/- and six combined Ptch1+/- Nos2-/- mice were analyzed. Healthy cerebellum taken from mice at postnatal day nine, six weeks after birth, and about 1 year of age were analyzed for wildtype animals and the genotypes Ptch1+/-, Ptch1+/- Nos2-/-, and Nos2-/-. The cerebellar developmental stages at six weeks and one year were measured in three biological replicates, while samples taken at postnatal day six consisted of pooled individual specimen. These were measured in three replicates being amplified and labelled in separate reactions. All samples were subjected to two-color hybridizations against Universal Reference RNA (Stratagene) with color-switch experiments yielding two technical replicates, respectively.
2011-12-01 | E-GEOD-29192 | biostudies-arrayexpress
Project description:Legionella pneumophila utilises a type IVB secretion system (T4SS) to translocate over 300 effectors into host cells, hijacking cellular processes, including those within the mitochondrion. Currently, no Legionella effectors have been identified at the mitochondrial outer membrane, a critical interface between the organelle and rest of the cell. We screened the Legionella effector repertoire for features of mitochondrial tail-anchored (TA) proteins and identified four putative TA effectors. Among them, Lpg1625 was confirmed to localize to the mitochondrial outer membrane and shown to interact with all three isoforms of protein phosphatase 1 (PP1) through an RVxF motif. Importantly, PP1 remains catalytically active upon interaction with Lpg1625, leading to dephosphorylation of specific mitochondrial outer membrane proteins. Altering the TA signature to direct Lpg1625 to the ER led to ER-recruitment of PP1 and subsequent dephosphorylation of ER resident proteins indicating that Lpg1625 controls PP1 localisation and not substrate specificity. This study uncovers a novel pathogen-mediated strategy to modulate PP1 and manipulate the host phosphoproteome.
2025-06-03 | PXD057005 | Pride
Project description:Global phosphoproteomic profiling of wild-type and TAK1-deficient B16F10 cells treated with TNF (10ng/ml) and IFNγ (1ng/ml) for one hour. The analysis reveals that TAK1 loss selectively disrupts phosphorylation of NF-κB and MAPK pathway components, including RELA, RIPK2, and MAP3K8, while STAT1-associated phosphorylation events remain intact, indicating that IFNγ–STAT1 signaling is TAK1 independent. Stratification of phosphosites highlights TAK1-sensitive sites, which are induced in wild-type but lost in TAK1 knockout cells, and TAK1-independent sites, which remain unaffected by TAK1 loss. Notably, phosphorylation of RIPK1 was altered: the inhibitory S25 site was reduced in TAK1-deficient cells, while a cluster of sites spanning Y309–S415 was more prominently phosphorylated, consistent with enhanced pro-death signaling. Together, these data show that TAK1 sustains NF-κB–driven survival signaling while restraining RIPK1 activation, thereby acting as a molecular switch that biases TNF and IFNγ signaling toward cytoprotection; its loss rewires cytokine signaling toward apoptosis.
2025-11-10 | PXD068715 | Pride
Project description:Little is known about metabolic vulnerabilities in oncogene-driven lung cancer. Here, we performed a phosphoproteomic screen in anaplastic lymphoma kinase (ALK)-rearranged (“ALK+”) patient-derived cell lines and identified guanylate kinase 1 (GUK1), a GDP-synthesizing enzyme, as a novel target of ALK signaling in lung cancer. We demonstrate that ALK binds to and phosphorylates GUK1 at tyrosine 74 (Y74), resulting in increased GDP biosynthesis. Spatially resolved mass spectrometry imaging of ALK+ patient tumor specimens shows enhanced phosphorylation of GUK1 that significantly correlates with guanine nucleotides in situ. Abrogation of GUK1 phosphorylation reduces intracellular GDP and GTP pools and decreases MAPK signaling through impaired Ras-GTP loading. A GUK1 variant that cannot be phosphorylated (Y74F) decreases tumor proliferation in vitro and in vivo. Beyond ALK, we determined that other oncogenic fusion proteins in lung cancer also regulate GUK1 phosphorylation. These studies may pave the way for the development of new therapeutic approaches by exploiting metabolic dependencies in oncogene-driven lung cancers.
2025-01-29 | PXD053405 | Pride